Nxera Pharma Establishes Metabolic Advisory Council to Advance Next-Generation Therapies for Obesity and Metabolic Disorders [Yahoo! Finance]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Yahoo! Finance
Tokyo, Japan and Cambridge, UK, 20 January 2026 – Nxera Pharma Co. Ltd (“Nxera” or “the Company; TSE 4565) today announces the formation of a Metabolic Advisory Council comprising world-leading industry experts to provide scientific, clinical, and strategic guidance as Nxera advances its rapidly growing pipeline of next-generation therapies targeting obesity and metabolic disorders. The three founding members of the council are: Professor Sir Stephen O'Rahilly , University of Cambridge – globally recognized for pioneering research into the genetic and molecular mechanisms of metabolic diseases and a scientific leader whose discoveries have shaped modern obesity and diabetes treatment. Professor Tricia Tan , Imperial College London – a distinguished clinician-scientist specializing in metabolic medicine and endocrinology, known for her translational research in appetite regulation and metabolic diagnostics. Dr. Mads Tang-Christensen , Novo Nordisk alumnus and biotech innovator
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Novo Nordisk expands diabetes cell therapy partnership with Aspect Biosystems [Yahoo! Finance Canada]Yahoo! Finance Canada
- Novo Nordisk (NYSE:NVO) Valuation Check After Sharp 1 Month Rebound And Mixed Long Term Returns [Yahoo! Finance]Yahoo! Finance
- Airlines have 580 million reasons to like GLP-1 weight-loss drugs, analysis finds [Yahoo! Finance]Yahoo! Finance
- Compounder sues Lilly and Novo for suppressing GLP-1RA competition [Yahoo! Finance]Yahoo! Finance
- Drugmakers hike medicine prices in 2026. How much more will you spend? [USA TODAY]USA TODAY
NVO
Earnings
- 11/6/25 - Beat
NVO
Sec Filings
- 12/23/25 - Form 6-K
- 11/25/25 - Form 6-K
- 11/24/25 - Form 6-K
- NVO's page on the SEC website